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Aim: Utilizing data from the Continuing to Confront COPD (chronic obstructive pulmonary 
disease) International Physician Survey, this study aimed to describe physicians’ knowledge 
and application of the GOLD (Global initiative for chronic Obstructive Lung Disease) Global 
Strategy for the Diagnosis, Management and Prevention of COPD diagnosis and treatment 
recommendations and compare performance between primary care physicians (PCPs) and 
respiratory specialists.
Materials and methods: Physicians from 12 countries were sampled from in-country profes-
sional databases; 1,307 physicians (PCP to respiratory specialist ratio three to one) who regu-
larly consult with COPD, emphysema, or chronic bronchitis patients were interviewed online, 
by telephone or face to face. Physicians were questioned about COPD risk factors, prognosis, 
diagnosis, and treatment, including knowledge and application of the GOLD global strategy 
using patient scenarios.
Results: Physicians reported using spirometry routinely (PCPs 82%, respiratory specialists 
100%; P,0.001) to diagnose COPD and frequently included validated patient-reported outcome 
measures (PCPs 67%, respiratory specialists 81%; P,0.001). Respiratory specialists were more 
likely than PCPs to report awareness of the GOLD global strategy (93% versus 58%, P,0.001); 
however, when presented with patient scenarios, they did not always perform better than PCPs 
with regard to recommending GOLD-concordant treatment options. The proportion of PCPs 
and respiratory specialists providing first- or second-choice treatment options concordant with 
GOLD strategy for a GOLD B-type patient was 38% versus 67%, respectively. For GOLD C 
and D-type patients, the concordant proportions for PCPs and respiratory specialists were 40% 
versus 38%, and 57% versus 58%, respectively.
Conclusion: This survey of physicians in 12 countries practicing in the primary care and respi-
ratory specialty settings showed high awareness of COPD-management guidelines. Frequent 
use of guideline-recommended COPD diagnostic practices was reported; however, gaps in the 
application of COPD-treatment recommendations were observed, warranting further evaluation 
to understand potential barriers to adopt guideline recommendations.
Keywords: chronic obstructive pulmonary disease, physician beliefs, adherence to 
guidelines
Introduction
Chronic obstructive pulmonary disease (COPD) is a chronic inflammatory lung dis-
ease that is complex and progressive, but which is also considered preventable and 
treatable.1 The multicomponent nature of COPD is now reflected in several regional 
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and international management guidelines2,3 and the recently 
released Global Strategy for the Diagnosis, Management and 
Prevention of COPD released by GOLD (Global initiative 
for chronic Obstructive Lung Disease).1 The GOLD global 
strategy outlines preferred diagnosis methods for COPD, 
including evaluation of signs/symptoms, assessment of 
patient history and past exposure to risk factors, and post-
bronchodilator spirometric confirmation. Once a COPD 
diagnosis is confirmed, the GOLD global strategy also recom-
mends a new disease-classification approach that combines 
symptoms (modified Medical Research Council [mMRC] 
dyspnea grade or COPD Assessment Test) and exacerbation 
risk (airflow limitation and/or history of exacerbations) to 
categorize patients into four groups from A (low risk, fewer 
symptoms) to D (high risk, more symptoms). Pharmaco-
logical treatment recommendations for disease management 
are provided for these groups, ranging from a short-acting 
anticholinergic and/or short-acting β
2
-agonist for group A 
patients to combined therapy with an inhaled corticosteroid 
(ICS) and a long-acting β
2
-agonist (LABA) or long-acting 
anticholinergic (long-acting muscarinic antagonist [LAMA]) 
for groups C and D (with the possibility of triple therapy with 
LAMA + ICS/LABA for group D) (Table 1).
Despite the availability of international disease-man-
agement guidelines, including those specifically aimed at 
primary care, COPD often remains underdiagnosed and 
inappropriately treated.4–7 A large web-based survey in 2011 
of primary care physicians (PCPs) across the regions of Asia 
Pacific, Africa, Eastern Europe, and Latin America showed 
limited knowledge of COPD guidelines, including underuti-
lization of spirometry for diagnosis of COPD and a general 
lack of awareness about the significance of exacerbations as 
an important factor in the management of COPD.8 Country-
specific surveys largely conducted in primary care in Western 
Europe,5,6,9–11 Japan,12 Mexico,13 and the USA14–16 have also 
shown that despite knowledge of guidelines, there is a lack 
of adherence to guideline recommendations for the treat-
ment of COPD. In the USA, the main barriers to guideline 
implementation have been reported as low familiarity, low 
ability or confidence in interpreting recommendations, 
Table 1 Initial pharmacological management of COPD*
Patient group First choice Second choice Alternative choices**
a short-acting anticholinergic Prn 
or 
short-acting β2-agonist Prn
long-acting anticholinergic 
or 
long-acting β2-agonist 
or 
short-acting β2-agonist and short-acting 
anticholinergic
Theophylline
B long-acting anticholinergic 
or 
long-acting β2-agonist
long-acting anticholinergic and 
long-acting β2-agonist
short-acting β2-agonist 
and/or 
short-acting anticholinergic 
Theophylline
C Inhaled corticosteroid + long-acting  
β2-agonist 
or 
long-acting anticholinergic
long-acting anticholinergic and long-acting  
β2-agonist
Phosphodiesterase-4 inhibitor 
short-acting β2-agonist 
and/or 
short-acting anticholinergic 
Theophylline
D Inhaled corticosteroid + long-acting  
β2-agonist 
or 
long-acting anticholinergic
Inhaled corticosteroid and long-acting  
anticholinergic 
or 
Inhaled corticosteroid + long-acting  
β2-agonist and long-acting anticholinergic 
or 
Inhaled corticosteroid + long-acting  
β2-agonist and phosphodiesterase-4 inhibitor 
or 
long-acting anticholinergic and long-acting  
β2-agonist 
or 
long-acting anticholinergic and  
phosphodiesterase-4 inhibitor
Carbocysteine 
short-acting β2-agonist 
and/or 
short-acting anticholinergic 
Theophylline
Notes: *Medications in each box are mentioned in alphabetical order, and thus not necessarily in order of preference; **medications in this column can be used alone or in 
combination with other options in the first and second columns. From the Global Strategy for Diagnosis, Management and Prevention of COPD 2014, © Global initiative for 
chronic Obstructive lung Disease (gOlD), all rights reserved. available from http://www.goldcopd.org.1
Abbreviations: COPD, chronic obstructive pulmonary disease; Prn, pro re nata (as needed).
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time constraints, and low outcome expectancy among 
physicians.15,16
The Continuing to Confront COPD International Physi-
cian Survey aimed to describe physician beliefs and behaviors 
related to COPD risk factors, prognosis, diagnosis, and treat-
ment in a broad sample of PCPs and respiratory specialists 
across 12 countries worldwide. The objective of this analysis 
was to describe physicians’ knowledge and application of the 
GOLD global strategy (2011 version) diagnosis and treatment 
recommendations and compare performance between PCPs 
and respiratory specialists.
Materials and methods
study design and participants
The Continuing to Confront COPD International Physician 
Survey was a survey of PCPs and respiratory specialists in 
12 countries (Brazil, France, Germany, Italy, Japan, Mexico, the 
Netherlands, Russia, South Korea, Spain, the UK, and the USA) 
conducted between January and May 2013. Physicians were 
required to consult with five or more patients with COPD, 
emphysema, or chronic bronchitis per month, on average.
The sample of physicians was drawn from in-country 
databases of professional associations (eg, American Medical 
Association) and registries with the aim of having a national 
sample of PCPs and respiratory specialists at a ratio of three 
to one. This ratio was determined a priority in order to ensure 
an adequate sample size of each physician type within each 
country, and was not intended to represent the ratio of these 
physicians types practicing, or treating patients with COPD 
in an individual country. Each sample was proportionate 
to the subnational regions in each country, with the excep-
tion of  Russia, where the sample was drawn to be roughly 
 representative of the general population of the 12 most devel-
oped and populous cities.
Data collection
A standardized questionnaire was used in all countries to 
assess physician knowledge of COPD-management guide-
lines, diagnosis and treatment practices for COPD, and 
beliefs about COPD risk, natural history, and treatment effec-
tiveness. The standardized questionnaire was translated into 
local languages in-country and reviewed by an independent 
translator and a local GlaxoSmithKline clinical advisor for 
accuracy and cultural relevance. The surveys were conducted 
online, by telephone, or face to face according to cultural 
preferences in each country, and were approximately 20 
minutes in duration. Where possible, more than one mode 
of survey methodology was offered to accommodate the 
preferences of the physicians and to minimize the rate of 
refusal (Table 2). Modest payments to physicians for their 
time completing the survey were permitted in line with coun-
try regulations. For quality-control purposes, a minimum of 
10% of interviews (all sampling methods) were validated by 
recontact or review of recorded interviews.
The sampling and screening process identif ied 
1,307 physicians who agreed to be interviewed, compris-
ing 200 physicians from the USA and approximately 100 
each in the remaining countries (Table 2). The response rate 
by country ranged from 10% (USA) to 38% (Spain). No 
association was observed between poor response rates and 
type of interview technique used (telephone/internet/face to 
face); countries with the lowest response rates had the highest 
rates of “noncontact” issues (data not shown). For the total 
study population, the proportion of PCPs and respiratory 
Table 2 Physician response rate, physician type, and survey method in each country: Continuing to Confront COPD International 
survey, 2012–2013
Country Physician response  
rate (%)
Physicians  
interviewed (n)
PCP/RS (n) Survey mode
Usa 10 200 151/49 Telephone
Mexico 18 101 75/26 Internet/telephone
Brazil 17 101 75/26 Internet/telephone
France 37 100 74/26 Internet
germany 35 100 75/25 Internet
Italy 21 100 74/26 Telephone
spain 38 100 75/25 Internet/telephone
UK 31 100 75/25 Internet
netherlands 21 101 74/27 Internet
russia 23 100 74/26 Internet/face to face
Japan 13 101 73/28 Internet/telephone/face to face*
south Korea 14 103 76/27 Internet/telephone/face to face*
Total 1,307 971/336
Note: *Face-to-face available only in capital cities, ie, Tokyo and seoul.
Abbreviations: COPD, chronic obstructive pulmonary disease; PCP, primary care physician; rs, respiratory specialist.
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specialists was 74% and 26%, respectively. The sample size 
of 1,307 physicians allowed for a sample precision of ±3.1% 
for population responses or proportions around 50%.
Outcome definitions
The primary objective of the present analysis was to describe 
physicians’ knowledge and application of the GOLD global 
strategy diagnosis and treatment recommendations and 
compare performance in applying these guidelines between 
PCPs and respiratory specialists.
To evaluate physician knowledge about COPD-manage-
ment guidelines, respondents were queried about whether 
they were aware of any local/countrywide COPD guidelines, 
and if so, to what degree these guidelines influenced their 
everyday treatment practice. Respondents were similarly 
queried about the GOLD global strategy recommendations 
and its influence on their practice.
Physician-diagnosis practices were assessed by present-
ing respondents with a predefined list of diagnostic tests 
and instructing them to indicate which test(s) they normally 
conduct in order to establish a diagnosis of COPD (physicians 
could answer “Yes”, “No”, or “Test not available” for each 
test). Respondents were also asked to name the three most 
important factors in a patient’s history when establishing a 
diagnosis of COPD.
Lastly, physician concordance with prescribing a GOLD 
global strategy-recommended treatment for different types 
of COPD patients was evaluated using patient case scenarios 
(see Table S1 for scenario descriptions). Each patient vignette 
was emblematic of a typical GOLD B, C, or D patient 
(respondents were not told the patients’ GOLD classification 
as part of the descriptive text). After the scenario was read 
to the respondents (or displayed online), they were asked to 
consider which medication(s) they would typically prescribe 
to such a patient. Respondents could pick one or more of the 
medication options from a prespecified list that included: 1) 
short-acting bronchodilator, 2) LAMA, 3) LABA, 4) ICS/
LABA combination inhaler, 5) theophylline, 6) roflumilast, 7) 
triple therapy (LAMA + LABA/ICS fixed-dose combination 
in two inhaler devices), or 8) oral corticosteroids (chronic 
use). Respondents could also specify other medications not 
included in the predefined list; these were reviewed, and those 
that matched one of the eight prespecified classes of drugs 
were recoded prior to data analysis. “Concordance” with 
GOLD strategy for this analysis was defined as selecting 
a GOLD global strategy first- or second-choice treatment 
option for the specific type of patient, regardless of whether 
a medication from the  alternative choice was also selected 
(Tables 1 and S1). Respondents could select multiple first- (or 
second)-choice options and still be considered concordant. 
The second-choice option “LAMA and LABA” (for GOLD 
B, C, or D) was not evaluated, because this combination was 
not included in the prespecified list (no LAMA/LABA fixed-
dose combination products were commercially available at 
the time of survey development). Given the prespecified 
response categories, we could not ascertain if a physician 
who selected both 1) LABA and 2) LAMA intended for the 
products to be used concomitantly or separately. For similar 
reasons, we did not evaluate the second-choice option of 
“LAMA and ICS” (for GOLD D). For the GOLD D patient 
scenario, if a respondent selected either LABA/ICS or LAMA 
and also selected roflumilast, we assumed that the physician 
intended to use these in combination, consistent with the 
indication for roflumilast for use as an add-on therapy to 
bronchodilator treatment.17 Respondents were considered 
“discordant” with GOLD strategy if they 1) selected neither a 
first- nor second-choice option, 2) selected a first- or second-
choice option(s) along with additional nonrecommended 
therapies, or 3) selected a medication from the alternative 
choice alone.
statistical analysis
In order to evaluate the hypothesis that PCPs and respiratory 
specialists vary with regard to key outcomes (utilization of 
GOLD global strategy-recommended diagnostic tests and 
guideline-concordant behavior), all countries were combined 
to obtain a sufficient sample size. While there was some 
heterogeneity observed across countries, the direction of 
association was similar (see Supplementary materials for 
country-specific data). These physician sample data are not 
weighted because standardized and reliable estimates of the 
key demographic parameters of the universe of physicians in 
each country were not readily available. Multivariate logistic 
regression models, built for each outcome separately, con-
sidered physician type as the main exposure and included 
potential confounding variables. While several potential con-
founders were considered (knowledge and influence of local/
professional guidelines, knowledge and influence of GOLD 
global strategy, sex, year since graduated medical school, and 
participation in COPD-based continuing education courses), 
only awareness of the GOLD global strategy was significantly 
associated with each outcome and with physician type in 
univariate analyses. Therefore, all models were adjusted for 
awareness of the GOLD global strategy and country, and the 
statistical tests reported herein represent the P-value of the 
physician-type β-coefficient from this final adjusted model.
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Results
Demographics of physician sample
In the global sample from 12 countries, approximately 
three-quarters of the physicians were male and about half 
graduated from medical school after 1990, with a simi-
lar pattern observed for PCPs and respiratory specialists 
(Table 3). The proportion of physicians in a multispecialty 
practice was slightly higher for PCPs (56%) compared with 
respiratory specialists (48%). Respiratory specialists were 
more likely to be practicing in urban/city areas (55% versus 
37% of PCPs) and to report that they treated COPD patients 
in an inpatient or hospital-based clinic (33% versus 14% 
of PCPs). Respiratory specialists had a higher case mix of 
COPD patients (59% reported at least a third of all patients 
they treat regularly have COPD versus 8% of PCPs). The 
majority of physicians had received some continuing educa-
tion on COPD (88% of respiratory specialists, 71% of PCPs), 
and most reported using the term “COPD” when discussing 
the diagnosis with their patients.
Across countries, the proportion of male physicians 
was greater in Japan and South Korea and lower in Russia 
compared with the total population; Russia had very few 
single-specialty practices, and fewer physicians in Japan 
reported that they received some continuing education on 
COPD (19% of PCPs; 43% of respiratory specialists). The 
type, setting, and location of practices showed some variation 
across countries (Table 3).
Knowledge of guidelines
Across all countries, a high awareness of any professional 
guidelines for COPD diagnosis/management, including local 
guidelines, was reported for both PCPs (85%) and respiratory 
specialists (97%) (P,0.001, Figure 1A). Results were gener-
ally consistent across countries, with the exception of France, 
where less than half of PCPs reported familiarity with any 
guidelines. The majority of physicians disclosed that profes-
sional guidelines informed their practice (88% of PCPs, 91% of 
respiratory specialists). Among those who stated that guidelines 
Table 3 Demographic characteristics of physicians by country: Continuing to Confront COPD International survey, 2012–2013
Total 
n=1,307
USA 
n=200
Mexico 
n=101
Brazil 
n=101
France 
n=100
Germany 
n=100
Italy 
n=100
PCP 
%
RS 
%
PCP 
%
RS 
%
PCP 
%
RS 
%
PCP 
%
RS 
%
PCP 
%
RS 
%
PCP 
%
RS 
%
PCP 
%
RS 
%
Male 75 77 68 96 75 69 79 62 84 65 65 84 74 81
Patient setting
  Outpatient* 
Inpatient†
86 
14
67 
33
99 
1
80 
20
61 
39
77 
23
77 
23
85 
15
93 
7
50 
50
87 
13
60 
40
100 
0
69 
31
Type of practice
  single specialty 
Multispecialty 
Other
42 
56 
1
50 
48 
2
69 
31 
0
76 
25 
0
37 
61 
1
65 
35 
0
29 
67 
4
50 
50 
0
49 
51 
0
77 
23 
0
20 
77 
3
40 
60 
0
66 
34 
0
81 
15 
4
graduated medical school
  Before 1980 
1980s 
1990s 
2000 or after
11 
35 
26 
25
13 
30 
35 
21
9 
35 
36 
19
29 
57 
10 
4
4 
9 
5 
75
12 
23 
39 
23
11 
17 
25 
45
19 
19 
35 
27
12 
46 
19 
20
0 
35 
50 
15
13 
31 
36 
11
0 
32 
52 
12
31 
58 
5 
5
23 
31 
31 
12
Practice location
  Central city 
suburb/small city/town 
rural area
37 
53 
10
55 
43 
2
18 
72 
11
39 
57 
4
81 
15 
4
85 
15 
0
79 
21 
0
81 
19 
0
31 
41 
28
31 
69 
0
24 
52 
24
52 
44 
4
27 
73 
0
46 
54 
0
Continuing COPD education, yes 71 88 85 96 55 96 39 89 61 73 89 100 88 100
Percentage of patients seen with COPD
  .50% 
31%–50% 
11%–30% 
#10%
2 
6 
30 
63
27 
32 
34 
7
1 
3 
28 
68
18 
47 
32 
2
3 
4 
44 
49
23 
27 
35 
15
3 
8 
41 
48
15 
31 
50 
4
0 
2 
20 
77
19 
54 
19 
8
3 
4 
40 
53
32 
32 
36 
0
1 
3 
17 
80
54 
27 
4 
15
Use term “COPD” when discussing 
diagnosis with patients, yes
91 95 99 100 97 100 85 100 88 92 95 100 53 77
Notes: *Includes ambulatory care clinic; †includes hospital-based clinic.
Abbreviations: COPD, chronic obstructive pulmonary disease; PCP, primary care physician; rs, respiratory specialist.
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did not inform their practice (n=123 [11%]), the reasons most 
frequently given were: “I prefer to use my clinical experience” 
(n=41), “Guidelines do not allow for tailoring treatment to dif-
ferent patient circumstances” (n=35), “Guideline-suggested 
choice is not available” (n=31), “Guideline is not relevant/
disagree with them” (n=27), and “Patient does not prefer/will 
not adhere to guideline-suggested choice” (n=18).
Respiratory specialists were statistically significantly 
more likely to report awareness of the GOLD global strat-
egy (58% of PCPs versus 93% of respiratory specialists, 
P,0.001, Figure 1B); some variability across countries 
was observed. Despite lower awareness of the GOLD global 
strategy, PCPs were more likely to report they had made 
changes to their management of COPD patients based on 
these guidelines (61% of PCPs versus 51% of respiratory 
specialists). Among all physicians who reported that they 
had made changes to their management as a result of the 
GOLD global strategy (n=500 [57%]), changes included 
“Using different therapies than those previously used” 
(59%), “Incorporating lung function measurements” (25%) 
and “Incorporating the use of the COPD Assessment Test 
patient-reported outcome instrument” (20%).
establishing a COPD diagnosis
Both PCPs and respiratory specialists reported frequently 
using spirometry testing to establish a COPD diagnosis 
(100% of respiratory specialists indicated they use spirom-
etry versus 82% of PCPs [P,0.001]) (Table 4). An average 
of 16% of PCPs reported that spirometry was not available 
in their practice, ranging from 0 to 5% (Russia, UK, Spain, 
Netherlands, Germany, Brazil) to 46% in France and 82% in 
Italy (Table S2). Despite the GOLD global strategy recom-
mendation that postbronchodilator spirometry is required for 
diagnosis and assessment of COPD severity, 22% and 15% of 
PCPs and respiratory specialists, respectively, indicated that 
they only use prebronchodilator spirometry. Patient-reported 
outcomes (eg, dyspnea measure or COPD Assessment Test) 
were used frequently by both PCPs (67%) and respiratory 
specialists (81%) as part of assessing COPD. Significantly 
greater proportions of respiratory specialists than PCPs 
reported the use of chest X-ray, blood tests/oximetry, bron-
chodilator responsiveness, computerized tomography or 
magnetic resonance imaging scans, and patient-reported 
outcome instruments. Diagnostic practices varied somewhat 
by country (Table S2).
Table 3 Demographic characteristics by country: Continuing to Confront COPD International survey, 2012–2013 (continued)
Spain 
n=100
UK 
n=100
NL 
n=101
Russia 
n=100
Japan 
n=101
SK 
n=103
PCP 
%
RS 
%
PCP 
%
RS 
%
PCP 
%
RS 
%
PCP 
%
RS 
%
PCP 
%
RS 
%
PCP 
%
RS 
%
Male 81 56 73 76 76 78 41 62 96 86 92 89
Patient setting
  Outpatient* 
Inpatient†
91 
9
72 
28
93 
7
24 
76
92 
8
85 
15
80 
20
62 
39
51 
49
32 
68
92 
8
96 
4
Type of practice
  single specialty 
Multispecialty 
Other
57 
40 
3
72 
24 
4
23 
77 
0
16 
84 
0
28 
70 
1
26 
70 
4
1 
99 
0
8 
92 
0
48 
52 
0
54 
46 
0
54 
41 
5
11 
74 
15
graduated medical school
  Before 1980 
1980s 
1990s 
2000 or after
17 
47 
23 
12
8 
40 
32 
20
13 
41 
25 
17
8 
8 
40 
40
10 
41 
30 
16
7 
15 
56 
19
5 
26 
24 
45
12 
19 
12 
58
8 
45 
32 
12
18 
36 
21 
25
4 
20 
43 
26
4 
22 
63 
11
Practice location
  Central city 
suburb/small city/town 
rural area
27 
63 
11
44 
56 
0
16 
67 
17
56 
44 
0
39 
58 
3
70 
30 
0
19 
80 
0
23 
73 
0
29 
55 
16
43 
39 
18
74 
22 
4
96 
4 
0
Continuing COPD education, yes 85 92 84 80 84 93 93 96 19 43 50 93
Percentage of patients seen with COPD
  51%–100% 
31%–50% 
11%–30% 
1%–10%
1 
2 
43 
53
40 
28 
32 
0
3 
4 
25 
68
40 
32 
28 
0
3 
2 
15 
80
26 
33 
33 
7
10 
33 
41 
16
54 
31 
12 
4
1 
0 
30 
69
14 
11 
64 
11
0 
1 
15 
84
4 
19 
56 
22
Use term “COPD” when discussing 
diagnosis with patients, yes
96 96 100 100 99 100 92 89 84 82 93 100
Notes: *Includes ambulatory care clinic; †includes hospital-based clinic.
Abbreviations: COPD, chronic obstructive pulmonary disease; PCP, primary care physician; rs, respiratory specialist; nl, the netherlands; sK, south Korea.
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In response to an open-ended question asking physicians 
to state up to three top patient factors they consider when 
establishing a COPD diagnosis, the most frequently reported 
indicators, as referenced in the GOLD global strategy, were 
“History of smoking/exposure to passive smoking” (PCPs 
73%, respiratory specialists 79%, P=0.031), and “Chronic 
symptoms of airflow obstruction” (PCPs 47%, respiratory 
specialists 56%, P=0.011) (Table 5). This pattern was 
generally consistent across countries, with the exception of 
Russia, where “Chronic symptoms of airflow obstruction” 
followed by “Chronic cough with phlegm” were most fre-
quently reported, and Mexico and Germany, where “History 
of smoking/exposure to passive smoking” followed by 
“Occupational exposure to smoke/fumes/dust” were most 
frequently reported (Table S3).
application of gOlD global  
strategy management guidelines  
using patient scenarios
For the GOLD category B patient scenario, only one in three 
PCPs (38%) provided a response that was concordant with 
treatment recommendations, with respiratory specialists 
statistically significantly more likely to provide a concordant 
answer (67%, P,0.001, Figure 2). The most commonly 
selected concordant option among both types of physi-
cians was LAMA (PCP 22%, respiratory specialists 39%). 
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A Primary care physicians 
Respiratory specialists
100%
80%
60%
40%
20%
0
B Primary care physicians 
Respiratory specialists
100%
80%
60%
40%
20%
0
Figure 1 awareness of (A) any professional guidelines and (B) 2011 gOlD global strategy guidelines.
Note: P,0.001 comparing total primary care physicians to respiratory specialists, adjusted for country.
Abbreviations: gOlD, global initiative for chronic Obstructive lung Disease; COPD, chronic obstructive pulmonary disease; nl, the netherlands; sK, south Korea.
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PCPs were far more likely to report a discordant option of 
either an ICS-containing regimen or alternative option (short-
acting bronchodilator or theophylline alone) than respiratory 
specialists. Across countries, a similar pattern was observed, 
with the exceptions of Germany, Italy, and Japan, where the 
concordance was similar for PCPs and respiratory special-
ists (Table S4).
In contrast to the GOLD category B patient, PCPs and 
respiratory specialists performed similarly (40% and 38%, 
respectively; P=0.181) for the GOLD category C patient sce-
nario (Figure 3). PCPs indicated that they would most likely 
prescribe ICS/LABA combination inhalers alone (16%), 
while respiratory specialists commonly selected LAMA alone 
(13%). The most commonly mentioned discordant option 
reported by both physician types was triple therapy, which 
is only recommended for the more severe GOLD D-type 
patient (PCPs 16%, respiratory specialists 23%). Country-
specific data were consistent with the main findings, other 
than in Spain, Germany, and Japan, where PCPs demonstrated 
higher levels of concordance versus respiratory specialists, 
and in Russia respiratory specialists were substantially more 
concordant than PCPs (Table S4).
For the GOLD category D patient scenario, both physician 
types performed similarly, with slightly over half providing 
a concordant response (P=0.513, Figure 4). The most com-
monly selected concordant option was triple therapy (27% 
of PCPs and 33% of respiratory specialists); ICS/LABA 
was also commonly selected. Discordant answers commonly 
included triple therapy in combinations not recommended 
by GOLD, including oral corticosteroids (PCPs 7%) and 
phosphodiesterase 4 inhibitors (respiratory specialists 10%). 
Countries that were not consistent with the overall pattern 
of concordance were the USA and Russia (less than 50% of 
PCPs and respiratory specialists were concordant) and Brazil 
and Germany (less than 50% of respiratory specialists were 
concordant) (Table S4).
Discussion
The Continuing to Confront COPD International Physician 
Survey aimed to describe PCPs’ and respiratory special-
ists’ beliefs and behaviors in relation to COPD diagnosis 
Table 4 Tests typically used to establish a COPD diagnosis, by physician type: Continuing to Confront COPD International survey, 
2012–2013
Diagnostic test PCP (n=971) 
%
RS (n=336) 
%
P-value*
Yes No Not available Yes No Not available
spirometry testing 82 2 16 100 0 0 ,0.001
 Prebronchodilator 
 Postbronchodilator 
 Both
22 
7 
69
15 
21 
64
Peak expiratory flow 55 29 16 43 51 6 ,0.001
Bronchodilator responsiveness 68 23 9 80 19 2 ,0.001
Oral corticosteroid responsiveness 38 52 9 28 65 7 ,0.001
Chest X-ray 76 11 13 89 10 2 ,0.001
Blood test/oximetry 45 32 23 69 27 4 ,0.001
CaT/CT/MrI scans 21 53 25 44 51 5 ,0.001
Patient-reported outcomes (eg, dyspnea 
measure or COPD-assessment test)
67 28 5 81 18 1 ,0.001
Note: *P-value comparing PCP to rs for responses of yes versus no/not available, adjusted for country and awareness of gOlD global strategy.
Abbreviations: COPD, chronic obstructive pulmonary disease; PCP, primary care physician; rs, respiratory specialist; CaT, computerized axial tomography; 
CT, computerized tomography; MrI, magnetic resonance imaging; gOlD, global initiative for chronic Obstructive lung Disease.
Table 5 Key indicators for considering a COPD diagnosis: 
Continuing to Confront COPD International survey, 2012–2013
Key indicator PCP 
(n=971) 
%
RS 
(n=336) 
%
P-value*
Chronic symptoms of airflow  
obstruction (ie, wheezing, dyspnea)
47 56 0.011
Chronic cough with phlegm/sputum 39 44 0.050
history of cigarette smoking/ 
exposure to passive smoking
73 79 0.031
Occupational exposure to smoke,  
fumes, or dust
20 16 0.064
Family history of emphysema/ 
bronchitis/COPD
14 13 0.778
Notes: *P-value comparing PCP to rs, adjusted for country and awareness of 
gOlD global strategy. Percentages within a physician type will sum to greater 
than 100%; results from an open-ended question asking physicians to provide the 
top three most important factors in a patient’s history when establishing a COPD 
diagnosis; no predefined list provided.
Abbreviations: COPD, chronic obstructive pulmonary disease; PCP, primary care 
physician; rs, respiratory specialist; gOlD, global initiative for chronic Obstructive 
lung Disease.
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and treatment. Most PCPs and respiratory specialists reported 
that professional guidelines for COPD diagnosis/management 
informed their practice, which was widely reflected in the 
frequent self-reported use of spirometry to establish a diag-
nosis of COPD. However, with respect to the application of 
the GOLD global strategy for COPD management, a large 
proportion of both PCPs and respiratory specialists chose 
nonconcordant treatments for different patient scenarios.
In the current survey of 12 countries, 85% of PCPs and 
97% of respiratory specialists reported an awareness of any 
professional guidelines for COPD diagnosis/management, 
including local guidelines, which is higher than that reported 
in a PCP survey in the USA, which showed that only between 
a third and a half are highly familiar with GOLD and/or 
American Thoracic Society/European Respiratory Society 
guidelines.14,15 We observed that significantly fewer PCPs 
(58%) were familiar with the GOLD global strategy com-
pared with respiratory specialists (93%), similar to findings 
in previous surveys.8,10 This may be related to perceptions 
that the new GOLD categories have limited application in 
primary care and the previous suggestion that development 
of new treatment algorithms should involve the primary care 
community in order to fully engage their support.18
Despite the GOLD global strategy recommendation 
that spirometry is required to make a clinical diagnosis of 
COPD, barriers to using spirometry have previously been 
cited as a lack of access to spirometers, cost of testing/
inadequate reimbursement for testing, patient reluctance to 
have the test, lack of familiarity with recommendation, and 
time constraints.15,16 The self-reported use of spirometry by 
physicians in the Continuing to Confront COPD International 
Physician Survey was 80%–100%, which is among the high-
est reported in similar surveys. In Aisanov et al, 10%–48% 
of physicians self-reported using spirometry as a COPD 
diagnostic tool,8 while other studies show that even when 
physicians agree on the importance of spirometry, the actual 
use is only 23%–54%.10,15 Self-reported spirometry use in 
our study is also higher than benchmarks of actual use cap-
tured in population-based electronic medical records and 
health care-claims databases in the USA and UK.19,20 In our 
PCPs (n=971)A
B
Concordant,
38%
Discordant,
62%
First choice
– LABA: 7% 
– LAMA: 22% 
– LABA, LAMA*: 8%
Second choice
LAMA and LABA: NE§ 
Alternative options alone (SABD or 
theophylline): 16%
ICS/LABA: 15%
LAMA, ICS/LABA*: 7%
Triple therapy: 5%
LAMA, ICS/LABA, triple therapy*: 3%
Other: 16%
Respiratory specialists (n=336)
First choice
– LABA: 7% 
– LAMA: 39% 
– LABA, LAMA*: 21%
Second choice
LAMA and LABA: NE§ 
Concordant,
67%
Discordant,
33%
Alternative options alone (SABD or
theophylline): 8%
ICS/LABA: 7%
Triple therapy: 6% 
LAMA, ICS/LABA*: 4% 
LAMA, ICS/LABA, triple therapy*: 2% 
Other: 7%
P<0.001¥
Figure 2 Proportion of (A) primary care physicians (PCPs) and (B) respiratory specialists concordant with first- or second-choice GOLD 2011 global strategy treatment 
options for gOlD category B patient.
Notes: Triple therapy defined as LAMA + LABA/ICS fixed-dose combination in two inhaler devices. gOlD B scenario: this patient has an mMrC dyspnea scale score of 2, a 
GOLD airflow-limitation classification of 2, and had one exacerbation in the past year. *respondent independently selected all listed treatment options; does not necessarily 
reflect the respondent’s intention to use these medications simultaneously; §second-choice option of laMa and laBa not evaluable; ¥P-value comparing PCPs to respiratory 
specialists, adjusted for country and awareness of the gOlD global strategy. Individual treatment choices may not add to concordant or discordant response percentage 
due to rounding.
Abbreviations: gOlD, global initiative for chronic Obstructive lung Disease; saBD, short-acting bronchodilator; laMa, long-acting muscarinic antagonist; laBa, long-
acting β2-agonist; ICS, inhaled corticosteroid; mMRC, modified Medical Research Council; NE, not evaluable. 
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population, only 16% of PCPs and 0 respiratory specialists 
reported that they did not have access to spirometry, which 
may in part explain the higher rate of spirometry use in our 
survey. However, we did observe a large variation in lack of 
access by country, ranging from 0 (Russia, UK) up to 46% 
(France) and 82% (Italy), reported by PCPs. While there are 
likely some true intercountry differences in the availability of 
spirometry, some of the variability observed may have been 
due to differences in understanding of the questionnaire (ie, 
some respondents interpreted a lack of access as no direct 
access to spirometry in their clinic, while others interpreted 
it as no direct access plus no access via a specialist).
While reported diagnostic practices appear largely to 
reflect guideline recommendations, application of the GOLD 
global strategy management guidelines was considerably 
lower. Despite respiratory specialists being significantly more 
likely to report knowledge of the GOLD global strategy, they 
did not perform appreciably better than PCPs in providing 
guideline-concordant answers, possibly suggesting that 
awareness does not necessarily translate into implementation, 
given the many variables that factor into the ultimate pre-
scribing decision (eg, physician experience, local formulary, 
costs, and patient preferences). These findings are similar to 
those reported in a survey of PCPs and practice nurses in the 
UK, which showed high awareness levels of national COPD 
guidelines were not reflected in diagnoses or management 
strategies when presented with several case scenarios.9
However, these concordance findings must be interpreted 
within the limitations of the data available, as clinical scenar-
ios are incomplete reflections of the complexity of physicians’ 
treatment decision making in the clinic, including the role of 
constraints faced by physicians with regard to formularies or 
local guidelines. For example, respiratory specialists in our 
survey showed a greater reluctance to change their practice 
or fully adopt guidelines, with many stating they prefer to 
rely on their clinical experience or feel that guidelines do 
PCPs (n=971)A
B
First choice
– ICS/LABA: 16% 
– LAMA: 11% 
– ICS/LABA, LAMA*: 13% 
Second choice
LAMA and LABA: NE§ 
Concordant,
40%
Discordant,
60%
Triple therapy: 16% 
Alternative options alone (SABD,
theophylline or PDE4 inhibitor): 8% 
LABA, LAMA*: 6% 
LABA: 5% 
LAMA, ICS/LABA, triple therapy*: 5% 
LABA, LAMA, ICS/LABA, triple 
therapy*: 5%
Other: 15%
Respiratory specialists (n=336)
First choice
– ICS/LABA: 10% 
– LAMA: 13% 
– ICS/LABA, LAMA*: 15% 
Second choice
LAMA and LABA: NE§ 
Concordant,
38%
Discordant,
62%
Triple therapy: 23% 
LABA, LAMA*: 13% 
LABA, LAMA, ICS/LABA, triple
therapy*: 6% 
LAMA, ICS/LABA, triple therapy*: 6%
Alternative options alone (SABD,
theophylline or PDE4 inhibitor): 3% 
Other: 10%
P=0.181¥
Figure 3 Proportion of (A) primary care physicians (PCPs) and (B) respiratory specialists concordant with first- or second-choice GOLD 2011 global strategy treatment 
options for gOlD category C patient.
Notes: Triple therapy defined as LAMA + LABA/ICS fixed-dose combination in two inhaler devices. gOlD C scenario: this patient has an mMrC dyspnea scale score of 0, 
a GOLD airflow-limitation classification of 3, and had one hospitalized exacerbation in the past year. *respondent independently selected all listed treatment options; does 
not necessarily reflect the respondent’s intention to use these medications simultaneously; §second-choice option of laMa and laBa not evaluable; ¥P-value comparing PCPs 
to respiratory specialists, adjusted for country and awareness of the gOlD global strategy. Individual treatment choices may not add to concordant or discordant response 
percentage due to rounding.
Abbreviations: gOlD, global initiative for chronic Obstructive lung Disease; saBD, short-acting bronchodilator; laMa, long-acting muscarinic antagonist; laBa, long-
acting β2-agonist; ICS, inhaled corticosteroid; mMRC, modified Medical Research Council; NE, not evaluable; PDE; phosphodiesterase.
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not adequately account for individual patient symptoms or 
circumstances, including ability to adhere to recommended 
medications. Further, our definition of a “concordant 
response” required a detailed knowledge of both the GOLD 
patient-severity schema (A–D) and the paired treatment 
recommendation for each patient type. PCPs in our sample 
were more likely to report following local guidelines, many of 
which have yet to adopt the GOLD patient-severity schema or 
have incorporated different multidimensional indices to define 
disease severity.21 As the GOLD global strategy evolves and 
is further incorporated into local guidelines, it will be of inter-
est to repeat this type of analysis to evaluate improvement in 
concordance among PCPs and respiratory specialists.
Another limitation of the data that may have affected 
the percentage reporting a concordant response was that we 
could not ascertain if a physician who selected the GOLD 
second-choice options of “LAMA and LABA” or “LAMA 
and ICS” intended for the products to be used together or as 
individual therapies. The impact of this limitation was likely 
to be minimal, however, as such combinations as “LABA and 
LAMA” were not commercially available in a single device, 
and concomitant prescriptions of the two medication classes 
were infrequent at the time of the survey.22
The inclusion of both PCPs and respiratory specialists 
in the Continuing to Confront COPD International Survey 
provides a unique opportunity to compare physician types 
with regard to attitudes and behaviors. However, the overall 
sample from each country was fairly small, making inter-
country comparisons challenging statistically. Further, the 
representativeness of the sample within certain countries may 
be limited due to low response rates. Such low response rates 
did not appear attributable to the type of interview technique 
First choice
– ICS/LABA: 10% 
– LAMA: 5% 
– ICS/LABA, LAMA*: 10% 
Second choice§
– Triple therapy: 27% 
– ICS/LABA + PDE4 inhibitor: <1% 
– LAMA + PDE4 inhibitor: <1% 
– Triple therapy, ICS/LABA + PDE inhibitor*: 0% 
– Triple therapy, LAMA + PDE4 inhibitor*: <1%
– ICS/LABA, LAMA + PDE4 inhibitor*: 1% 
Combinations of first and second choice
– Triple therapy, ICS/LABA*: 1% 
– Triple therapy, LAMA*: 1% 
– Triple therapy, ICS/LABA, LAMA*: 2% 
Concordant,
57%
Discordant,
43%
Triple therapy, OCS*: 7% 
LABA, LAMA, LABA/ICS, triple therapy*: 4% 
LABA: 4% 
LABA, LAMA, LABA/ICS*: 3% 
LAMA, ICS/LABA, triple therapy, OCS*: 2% 
Other: 24% 
Respiratory specialists (n=336)
PCPs (n=971)A
B
First choice
– ICS/LABA: 4% 
– LAMA: 2% 
– ICS/LABA, LAMA*: 10% 
Second choice§
– Triple therapy: 33% 
– ICS/LABA + PDE4 inhibitor: 1% 
– LAMA + PDE4 inhibitor: <1% 
– Triple therapy, ICS/LABA + PDE4 inhibitor*: 1%
– Triple therapy, LAMA + PDE4 inhibitor*: 1% 
– ICS/LABA, LAMA + PDE4 inhibitor*: 2% 
Combinations of first and second choice
– Triple therapy, ICS/LABA*: 1% 
– Triple therapy, LAMA*: 1% 
– Triple therapy, ICS/LABA, LAMA*: 2%
Concordant,
58%
Discordant,
42%
Triple therapy, PDE4 inhibitor*: 10% 
LABA, LAMA, LABA/ICS, triple therapy,
PDE4 inhibitor*: 4%
LABA: 3% 
LABA, LAMA, LABA/ICS, triple therapy:* 2% 
LABA, LAMA*: 2% 
Other: 20% 
P=0.513¥
Figure 4 Proportion of (A) primary care specialists (PCPs) and (B) respiratory specialists concordant with first- or second- choice GOLD 2011 global strategy treatment 
options for gOlD category D patient.
Notes: Triple therapy defined as LAMA + LABA/ICS fixed-dose combination in two inhaler devices. gOlD D scenario: this patient has an mMrC dyspnea scale score 
of 2, a GOLD airflow-limitation classification of 3, and had two exacerbations in the past year. *respondent independently selected all listed treatment options; does not 
necessarily reflect the respondent’s intention to use these medications simultaneously; §second-choice options of 1) laMa and laBa and 2) ICs and laMa not evaluable; 
¥P-value comparing PCPs to respiratory specialists, adjusted for country and awareness of gOlD global strategy. Individual treatment choices may not add to concordant 
or discordant response percentage due to rounding.
Abbreviations: gOlD, global initiative for chronic Obstructive lung Disease; OCs, oral corticosteroid; laMa, long-acting muscarinic antagonist; laBa, long-acting 
β2-agonist; ICS, inhaled corticosteroid; mMRC, modified Medical Research Council; PDE; phosphodiesterase.
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used in the survey, but were most notable in countries with 
the greatest issues relating to physician “contact”, and this, 
together with incentivizing respondents with a modest 
financial reward, may have introduced some responder bias. 
However, low physician response rates and varied response 
by country (10% in the USA to 38% in Spain) were broadly 
consistent with ranges previously reported in published 
surveys of representative physician samples,10,23,24 and may 
reflect the two-stage process of this survey (initial contact 
by post/email that invited the physician to contact the survey 
research organization for an appointment to complete the 
questionnaire at their convenience).
In summary, this global survey of PCPs and respiratory 
specialists showed high awareness of COPD-management 
guidelines. These guidelines appear to be widely followed by 
both PCPs and respiratory physicians with regard to diagnostic 
practices, including reported use of spirometry and frequent 
consideration of risk factors, including smoking history, symp-
tom presentation, and family history. However, there appears 
to be less adoption of guidelines when applied to COPD treat-
ment choice, with fewer physicians of both types selecting a 
suggested GOLD global strategy treatment choice in patient 
scenarios. Further research is needed to better understand the 
barriers to implementing treatment recommendations and 
rationale for alternative treatment choices using a tailored 
approach for different medical specialties. These data can 
inform physician-education strategies and public health infra-
structure relevant to country-specific/local guidelines with the 
aim to improve COPD disease management and outcomes.
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